Phisanu Pooruk. Production of mouse monoclonal antibodies to HIV-1 Gag epitope(S) by using HIV-1 CRF01_AE as immunogen . Master's Degree(Microbiology). Mahidol University. : Mahidol University, 2003.
Production of mouse monoclonal antibodies to HIV-1 Gag epitope(S) by using HIV-1 CRF01_AE as immunogen
Abstract:
The present study aimed to establish the mouse hybridoma cell lines which secreted
MAbs specific to HIV-1/Gag epitope(s) by using somatic hybridoma technique. Suspension of
HIV-1 CRF01_AE strain DA5 inactivated with either formaldehyde or Nonidet P40 was used
as the immunogen. Each immunizing dose was composed of approximately 40,000 TCID50 of
HIV-1, with contained p24 antigen concentration of 9 ng. Immunization was done by 4
intraperitoneal injections followed by one intravenous injection at 2 week-intervals.
Splenocytes from the immunized BALB/c mice were allowed to fuse with the nonsecreting
myeloma cells designated P3X63-Ag 8.653.
Screening for HIV-specific MAbs was performed by commercial ELISA (Organon
Teknika), and immunofluorescence (IF) test involving HIV-1 infected H9 cells as the test
antigens. Then, these hybrids were further screened for specificity to Gag protein by
commercial western blot (WB) and by IF using TK cells infected with HIV-1 gag A/vaccinia
recombinant as the antigen.
Seven MAb secreting clones which were specific to Gag protein have been established.
All of them were originated from mice immunized with formaldehyde treated viruses. Isotypic
characterization demonstrated that all seven MAbs had IgM isotype with kappa light chain
characteristic.
Two clones: F-1-8C1-E4C12 and F-2-8C12-H3-H3 derived from different origins were
selected for larger scale production, and then, concentrated by ammonium sulfate precipitation
or IgM affinity chromatography. Specificity of these concentrated MAbs was reconfirmed by
commercial ELISA, IF and dot blot using refolded recombinant Gag protein as the antigen.
Collective information from all immunological tests revealed that the two MAbs
possessed the following properties: 1) cross reacted with subtype A (as tested against HIV-1
gag A/vaccinia recombinant) and to subtype B viruses (as tested by commercial ELISA
Ortho-Clinical Diagnostics, Inc. and Murex Biotech Limited); 2) reacted with conformational
epitope(s) of Gag protein. Further characterization and application of these two MAbs in HIV
research are to be further investigated